COMMUNIQUÉS West-GlobeNewswire

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
03/12/2025
– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million – Fiscal 2025 revenue increased 4.5% to $513.0 million – Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million – Fiscal 2025 operating [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the [...]
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
03/12/2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/12/2025
BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
HealthEquity Reports Third Quarter Ended October 31, 2025 Financial Results
03/12/2025
Highlights of the third quarter include: Revenue increased 7% to $322.2 million. Net income per diluted share rose to $0.59 from $0.06 one year ago, and non-GAAP net income per diluted share increased 29% to $1.01. [...]
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
03/12/2025
Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously [...]
Most Popular Legal Steroids for Muscle Building from CrazyBulk: Legal Steroid Alternatives for Lean Muscle Growth and Cutting in 2026
03/12/2025
Most Popular Legal Steroids for Muscle Building from CrazyBulk: Best-Selling Steroid Alternatives for Lean Muscle Growth and Cutting in 2026 CrazyBulk has emerged as one of the most trusted names in the world of legal [...]
Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance
03/12/2025
With evidence-based clinical development and new pharmaceutical formulations, Avextra aims to increase patient experience and adherence Bensheim, Germany – 3. December 2025 – How can therapy with Cannabis-based [...]
Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets
03/12/2025
CHICAGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced a long-term strategic [...]
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
03/12/2025
PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak [...]
Wake Radiology UNC Health Rex Announces the Retirement of Body Imaging Radiologist Dr. Imre Gaal Jr.
03/12/2025
Raleigh, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex, the largest outpatient imaging provider in the Triangle, today announced the retirement of distinguished Body Imaging Radiologist Imre Gaal [...]
Nika Pharmaceuticals, Inc. (NIKA) Progress Update
03/12/2025
HENDERSON, Nev., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) appeared on The Street Reports podcast where CEO Dimitar Savov shared the progress the company has made thus far and outlined [...]
Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology
03/12/2025
Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line therapy for uHCC The combination continued to show clinically meaningful survival improvement [...]
BetaGlue Therapeutics étend son essai clinique en Italie après avoir obtenu l’autorisation du ministère de la Santé italien pour mener son étude clinique sur le cancer du pancréas localement avancé non résécable (uLA-PDAC)
03/12/2025
MILAN, 03 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société d’oncologie en phase clinique développant une solution innovante de radiothérapie pour le traitement ciblé [...]
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
03/12/2025
Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the [...]
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
03/12/2025
Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the [...]
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
03/12/2025
MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related [...]
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
03/12/2025
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the expiration of the initial [...]
Wesley Pharmaceuticals Unveils First Product, Zinc Sulfate, Revolutionizing Wellness Solutions
03/12/2025
Debut product from the innovative 503(b) outsourcing facility delivers enhanced wellness to Olympia Pharmaceutical clients, marking a new era of innovation ORLANDO, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Wesley [...]

Pages